BAY 94-9027 Maintains Hemostasis During Major Surgery in Adults and Adolescents With Severe Hemophilia A: PROTECT VIII Results
Objective: BAY 94-9027 is an extended–half-life recombinant factor VIII (FVIII) product. Efficacy in maintaining hemostasis during major surgery was evaluated in a subset of patients with severe hemophilia A in the phase 2/3…
A retrospective chart review to assess clinical characteristics of women and girls with factor VIII and IX deficiency
Objective: Evaluate clinical characteristics, hemostasis management, and clinical outcomes regarding menstruation, child birth, surgical procedures, dental care, and spontaneous and traumatic bleeds of women and…
Start the Conversation with The Fellow on Call
This Bleeding Disorders Awareness Month, hematologists Ronak Mistry, DO and Dan Hausrath, MD start a conversation around their experiences being early career physicians, and launching a podcast. Watch their video and read a transcript. Learn more…
A Multicenter, Retrospective Data Collection Study on the Compassionate Use of a Plasma-Derived Factor X Concentrate to Treat Patients with Hereditary Factor X Deficiency
Objective: Report results of an open-label international study that collected retrospective data on compassionate use of high-purity plasma-derived FX concentrate (pdFX) in subjects with hereditary factor X (FX) deficiency (FXD…
Government Relations Update – February 2026
Federal:  NBDF Wraps Up Another Successful Washington DaysLast week, 357 advocates met with 244 different offices on Capitol Hill as part of NBDF’s annual Washington Days to talk about issues important to…